Analyzing the Treatment Cost of Liver Cirrhosis from Healthcare Payer’s Perspective of Vietnam in 2015

Abstract

A633 cost, drugs cost accounted for the highest proportion with 44.52%; the lower is the clinical test cost with 21.67% (3,376,153.70 and 1,643,644.83 VND; respectively). The influential factors on costs of treatment included the place of residence, the number of days in hospital, the stage and the complications of cirrhosis. ConClusions: With the rising trend of liver cirrhosis in Vietnam and the high cost of treatment, national health policies and medical programs should be considered.

Economic costs of terminal care for selected non-communicable diseases from a healthcare perspective: a review of mortality records from a tertiary hospital in Nigeria

“…In a study of patients with cirrhosis in Vietnem, Nguyen et 39 of which almost 69% of the costs were covered by health insurance. 20 Although comparisons between our estimates and those provided by the studies cited above need to be made with caution because of our small sample, variations in the disease stage, exact types and duration of treatment provided (among other variables), our findings confirm that irrespective of the setting, the amount expended to treat each of the diseases considered is significant. Boutayeb and Boutayeb in their review of the burden of NCDs in low-income and middle-income countries highlighted the huge difference in costs expended in managing NCDs between patients in developed and low-income and middle-income countries and between affluent and poor patients within developed countries noting that this reflected inequity in access to treatment.…”

“…In a study of patients with cirrhosis in Vietnem, Nguyen et al estimated that the median cost of treatment per session in 2015 was VND7 439 527.40±VND52 514 030.97, that is, approximately US$329.90±US$232.88 (US$1 in VND:US$22 550.18 for 31 December 2015) 39 of which almost 69% of the costs were covered by health insurance. 20 …”

“…13 14 There has been an increase in the numbers of studies documenting the cost of various NCDs, however, the overwhelming majority of these studies have been conducted in developed countries or in low-income and middleincome countries in Asia. [15][16][17][18][19][20][21] Data from existing studies confirm the immense economic burden from NCDs. Muka et al in their review of the global impact of NCDs on healthcare found that globally, cancer and CVDs had the highest reported mean annual total direct costs per patient of approximately US$197 772 and US$81 096, respectively.…”